Work

A phase II study to evaluate the safety and efficacy of RAD001 plus erlotinib in patients with well-differentiated neuroendocrine tumors (NET).

Year: 2012

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2012.30.4_suppl.285

Authors: Emily K. Bergsland, Lindsey Watt, Andrew H. Ko, Margaret A. Tempero, Wolfgang Michael Korn, Robin Katie Kelley, Thomas Weber, Iche Siah, Jimmy Hwang, Eric K. Nakakura, Alan Paul Venook

Institutions: University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center

Language: English

Topic: Neuroendocrine Tumor Research Advances

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2534615596

Cites:

Cited by: 7

Related to: 10